Search
PERJETA 420 MG, Solution pour perfusion
Details
| --- | Description |
|---|---|
| Pack | 1 flacon de 20 ml |
| Strength (Dosage) | 420 MG |
| Laboratory | ROCHE S.A |
| Ingredients | Pertuzumab |
| Therapeutic class | Antinéoplasique, anticorps monoclonal (anti-HER2) |
| ATC code | L01XC13 |
| PPH | $2,540.00 |
| PPV | $2,590.00 |
| Refundable | Yes |
| Refund base | $2,590.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | Cancer du sein précoce Perjeta est indiqué en association au trastuzumab et à une chimiothérapie, dans : - le traitement néoadjuvant de patients adultes atteints d'un cancer du sein HER2 positif localement avancé, inflammatoire ou à un stade précoce avec un risque élevé de récidive. - le traitement adjuvant de patients adultes atteints d'un cancer du sein précoce HER2 positif avec un risque élevé de récidive. Cancer du sein métastatique Perjeta est indiqué en association au trastuzumab et au docétaxel, dans le traitement de patients adultes atteints d’un cancer du sein métastatique ou localement récidivant non résécable HER2 positif, n’ayant pas reçu au préalable de traitement anti-HER2 ou de chimiothérapie pour leur maladie métastatique. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem